tetano
Editor, Senior Moderator
NPJ Vaccines. 2017 Nov 20;2:32. doi: 10.1038/s41541-017-0031-7. eCollection 2017.
[h=1]Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine.[/h] Wei H[SUP]#[/SUP][SUP]1[/SUP], Chen Z[SUP]#[/SUP][SUP]1,[/SUP][SUP]2[/SUP], Elson A[SUP]1,[/SUP][SUP]3[/SUP], Li Z[SUP]1[/SUP], Abraham M[SUP]1[/SUP], Phan S[SUP]1[/SUP], Kristhnamurthy S[SUP]4[/SUP], McCray PB Jr[SUP]4[/SUP], Andrews S[SUP]5[/SUP], Stice S[SUP]5[/SUP], Sakamoto K[SUP]6[/SUP], Jones C[SUP]1[/SUP], Tompkins SM[SUP]1[/SUP], He B[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Delivery of a gene of interest to target cells is highly desirable for translational medicine, such as gene therapy, regenerative medicine, vaccine development, and studies of gene function. Parainfluenza virus 5 (PIV5), a paramyxovirus with a negative-sense RNA genome, normally infects cells without causing obvious cytopathic effect, and it can infect many cell types. To exploit these features of PIV5, we established a system generating self-amplifying, virus-like particles (AVLP). Using enhanced green fluorescent protein (EGFP) as a reporter, AVLP encoding EGFP (AVLP-EGFP) successfully delivered and expressed the EGFP gene in primary human cells, including stem cells, airway epithelial cells, monocytes, and T cells. To demonstrate the application of this system for vaccine development, we generated AVLPs to express the HA and M1 antigens from the influenza A virus strain H5N1 (AVLP-H5 and AVLP-M1H5). Immunization of mice with AVLP-H5 and AVLP-M1H5 generated robust antibody and cellular immune responses. Vaccination with a single dose of AVLP-H5 and M1H5 completely protected mice against lethal H5N1 challenge, suggesting that the AVLP-based system is a promising platform for delivery of desirable genes.
PMID: 29263887 PMCID: PMC5696535 DOI: 10.1038/s41541-017-0031-7
[h=1]Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine.[/h] Wei H[SUP]#[/SUP][SUP]1[/SUP], Chen Z[SUP]#[/SUP][SUP]1,[/SUP][SUP]2[/SUP], Elson A[SUP]1,[/SUP][SUP]3[/SUP], Li Z[SUP]1[/SUP], Abraham M[SUP]1[/SUP], Phan S[SUP]1[/SUP], Kristhnamurthy S[SUP]4[/SUP], McCray PB Jr[SUP]4[/SUP], Andrews S[SUP]5[/SUP], Stice S[SUP]5[/SUP], Sakamoto K[SUP]6[/SUP], Jones C[SUP]1[/SUP], Tompkins SM[SUP]1[/SUP], He B[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Delivery of a gene of interest to target cells is highly desirable for translational medicine, such as gene therapy, regenerative medicine, vaccine development, and studies of gene function. Parainfluenza virus 5 (PIV5), a paramyxovirus with a negative-sense RNA genome, normally infects cells without causing obvious cytopathic effect, and it can infect many cell types. To exploit these features of PIV5, we established a system generating self-amplifying, virus-like particles (AVLP). Using enhanced green fluorescent protein (EGFP) as a reporter, AVLP encoding EGFP (AVLP-EGFP) successfully delivered and expressed the EGFP gene in primary human cells, including stem cells, airway epithelial cells, monocytes, and T cells. To demonstrate the application of this system for vaccine development, we generated AVLPs to express the HA and M1 antigens from the influenza A virus strain H5N1 (AVLP-H5 and AVLP-M1H5). Immunization of mice with AVLP-H5 and AVLP-M1H5 generated robust antibody and cellular immune responses. Vaccination with a single dose of AVLP-H5 and M1H5 completely protected mice against lethal H5N1 challenge, suggesting that the AVLP-based system is a promising platform for delivery of desirable genes.
PMID: 29263887 PMCID: PMC5696535 DOI: 10.1038/s41541-017-0031-7